Analysts Set GSK plc (LON:GSK) PT at GBX 1,917.86

Shares of GSK plc (LON:GSK) have been given a consensus recommendation of “Hold” by the seven analysts that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is GBX 1,917.86.

A number of research firms have weighed in on GSK. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. Citigroup increased their price target on shares of GSK from GBX 1,900 to GBX 2,250 and gave the stock a “buy” rating in a research report on Monday, February 9th. Berenberg Bank upped their price target on GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a report on Monday, November 24th. UBS Group reissued a “neutral” rating and issued a GBX 1,940 target price on shares of GSK in a report on Friday, January 23rd. Finally, Shore Capital Group restated a “buy” rating and set a GBX 2,300 target price on shares of GSK in a research report on Wednesday, February 4th.

Insider Activity at GSK

In other GSK news, insider Wendy Becker purchased 441 shares of the stock in a transaction that occurred on Friday, December 19th. The shares were acquired at an average cost of GBX 1,809 per share, with a total value of £7,977.69. Also, insider Luke Miels sold 15,579 shares of GSK stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of GBX 2,160, for a total transaction of £336,506.40. In the last ninety days, insiders bought 4,597 shares of company stock worth $9,082,343. Insiders own 0.20% of the company’s stock.

GSK Price Performance

Shares of GSK stock opened at GBX 2,237.43 on Tuesday. The business has a 50-day moving average price of GBX 1,915.02 and a 200 day moving average price of GBX 1,716.42. GSK has a twelve month low of GBX 1,242.50 and a twelve month high of GBX 2,282. The firm has a market cap of £90.28 billion, a PE ratio of 16.82, a P/E/G ratio of 1.24 and a beta of 0.31. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64.

GSK (LON:GSK) last posted its earnings results on Wednesday, February 4th. The company reported GBX 172 earnings per share for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Sell-side analysts predict that GSK will post 175.980975 earnings per share for the current fiscal year.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.